
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France’s Servier for up to $2.65 billion. The French drugmaker ...
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France’s Servier for up to $2.65 billion. The French drugmaker ...